Us Bancorp \De\ Atreca, Inc. Transaction History

Us Bancorp \De\

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$4.91 - $9.07 $491 - $907	-100 Reduced 5.88%	1,600 $10,000
Q1 2021 Apr 28, 2021	BUY	$13.0 - $19.34 $10,400 - $15,472	800 Added 88.89%	1,700 $26,000
Q4 2020 Feb 04, 2021	SELL	$13.03 - $17.09 $11,727 - $15,381	-900 Reduced 50.0%	900 $15,000
Q3 2020 Nov 10, 2020	SELL	$12.67 - $23.19 $12,670 - $23,190	-1,000 Reduced 35.71%	1,800 $25,000
Q1 2020 May 13, 2020	BUY	$11.4 - $27.28 $31,920 - $76,384	2,800 New	2,800 $46,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.